Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling

Journal of Pathology

Volumn 223, Issue 4, 2011, Pages 496-510

  Ng, Siok Bian ^a   Selvarajan, Viknesvaran ^a   Huang, Gaofeng ^a   Zhou, Jianbiao ^b   Feldman, Andrew L ^c   Law, Mark ^c   Kwong, Yok Lam ^d   Shimizu, Norio ^e   Kagami, Yoshitoyo ^f   Aozasa, Katsuyuki ^g   Salto Tellez, Manuel ^a,b   Chng, Wee Joo ^a,b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c MAYO CLINIC   (United States)

^d QUEEN MARY HOSPITAL   (Hong Kong)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f Department of Clinical Laboratory   (Japan)

^g OSAKA UNIVERSITY   (Japan)

Author keywords

gene expression profiling; Myc; NF B; NK T cell lymphoma; p53; paraffin embedded tissue; survivin

Indexed keywords

AURORA A KINASE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POLO LIKE KINASE 1; PROTEIN P53; SURVIVIN; TERAMEPROCOL;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC MODEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NK T CELL LYMPHOMA; ONCOGENE C MYC; PHENOTYPE; PRIORITY JOURNAL; TISSUE MICROARRAY; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NF-KAPPA B; NORDIHYDROGUAIARETIC ACID; NOSE NEOPLASMS; ONCOGENES; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 79551696483     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2823     Document Type: Article

References (49)

1. Chan JKC, Quintanilla-Martinez L, Ferry JA, et al., Extranodal NK/T-cell lymphoma, nasal type. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th edn), Swerdlow SH, Campo E, Harris NL, et al. (eds). IARC Press: Lyon, 2008; 285-288.
2. Kanavaros P, Briere J, Emile JF, et al., Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas. Leukemia 1996; 10 (Suppl 2): s84-s87. (Pubitemid 126754016)
3. Xu ZG, Iwatsuki K, Oyama N, et al., The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas. Br J Cancer 2001; 84: 920-925. (Pubitemid 32385835)
4. Quintanilla-Martinez L, Kremer M, Keller G, et al., p53 mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. Am J Pathol 2001; 159: 2095-2105. (Pubitemid 33104264)
5. Takahara M, Kishibe K, Bandoh N, et al., P53, N- and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan. Hum Pathol 2004; 35: 86-95. (Pubitemid 38133927)
6. Takakuwa T, Dong Z, Nakatsuka S, et al., Frequent mutations of Fas gene in nasal NK/T cell lymphoma. Oncogene 2002; 21: 4702-4705. (Pubitemid 34833148)
7. Yamaguchi M, Kita K, Miwa H, et al., Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995; 76: 2351-2356.
8. Bossard C, Belhadj K, Reyes F, et al., Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2007; 109: 2183-2189. (Pubitemid 46348221)
9. Wong KF,. Genetic changes in natural killer cell neoplasms. Leuk Res 2002; 26: 977-978. (Pubitemid 35287205)
10. Iqbal J, Kucuk C, Deleeuw RJ, et al., Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 2009; 23: 1139-1151.
11. Huang Y, de Reynies A, de Leval L, et al., Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 2010; 115: 1226-1237.
12. Hoshida Y, Villanueva A, Kobayashi M, et al., Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
13. Liu X, Wang B, Ma X, et al., NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type. Jpn J Clin Oncol 2009; 39: 418-424.
14. Drexler HG, Matsuo Y,. Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma. Leukemia 2000; 14: 777-782. (Pubitemid 30235051)
15. Matsuo Y, Drexler HG,. Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. Leuk Res 2003; 27: 935-945. (Pubitemid 36809090)
16. Fan JB, Yeakley JM, Bibikova M, et al., A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res 2004; 14: 878-885. (Pubitemid 38660505)
17. Bibikova M, Talantov D, Chudin E, et al., Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol 2004; 165: 1799-1807. (Pubitemid 39435177)
18. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116-5121. (Pubitemid 32397092)
19. Ekins S, Nikolsky Y, Bugrim A, et al., Pathway mapping tools for analysis of high content data. Methods Mol Biol 2007; 356: 319-350.
20. Remstein ED, Dogan A, Einerson RR, et al., The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 2006; 30: 1546-1553. (Pubitemid 44815508)
21. Ambrosini G, Adida C, Sirugo G, et al., Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998; 273: 11177-11182. (Pubitemid 28204967)
22. Chang CC, Heller JD, Kuo J, et al., Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A 2004; 101: 13239-13244. (Pubitemid 39209649)
23. Marumoto T, Zhang D, Saya H, Aurora-A - a guardian of poles. Nature Rev Cancer 2005; 5: 42-50.
24. Strebhardt K, Ullrich A,. Targeting polo-like kinase 1 for cancer therapy. Nature Rev Cancer 2006; 6: 321-330.
25. Malumbres M, Barbacid M, Cell cycle, CDKs and cancer: a changing paradigm. Nature Rev Cancer 2009; 9: 153-166.
26. Annunziata CM, Davis RE, Demchenko Y, et al., Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115-130. (Pubitemid 47199123)
27. Huang G, Chng WJ,. Predicting the oncogenic pathway activities of individual samples from microarray gene expression profiles. In 2009 International Workshop on Computational and Integrative Biology (CIB 2009), Hangzhou, China, 2009; 20-25.
28. Kwong YL,. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005; 19: 2186-2194.
29. Li Q, Verma IM,. NF-kappaB regulation in the immune system. Nature Rev Immunol 2002; 2: 725-734.
30. Okamoto T, Sanda T, Asamitsu K,. NF-kappa B signaling and carcinogenesis. Curr Pharm Des 2007; 13: 447-462.
31. Izban KF, Ergin M, Qin JZ, et al., Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. Hum Pathol 2000; 31: 1482-1490. (Pubitemid 32047000)
32. Mathas S, Johrens K, Joos S, et al., Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 2005; 106: 4287-4293. (Pubitemid 41775938)
33. Kim K, Ryu K, Ko Y, et al., Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells. Br J Haematol 2005; 131: 59-66. (Pubitemid 43899708)
34. Li T, Hongyo T, Syaifudin M, et al., Mutations of the p53 gene in nasal NK/T-cell lymphoma. Lab Invest 2000; 80: 493-499. (Pubitemid 30226631)
35. Shen L, Au WY, Guo T, et al., Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation. Blood 2007; 110: 469-470. (Pubitemid 47026871)
36. Keats JJ, Fonseca R, Chesi M, et al., Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-144. (Pubitemid 47208626)
37. Compagno M, Lim WK, Grunn A, et al., Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717-721.
38. Kaiser C, Laux G, Eick D, et al., The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol 1999; 73: 4481-4484. (Pubitemid 29189900)
39. Dirmeier U, Hoffmann R, Kilger E, et al., Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene 2005; 24: 1711-1717. (Pubitemid 40461127)
40. Devergne O, Hatzivassiliou E, Izumi KM, et al., Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 1996; 16: 7098-7108. (Pubitemid 26389769)
41. Faumont N, Durand-Panteix S, Schlee M, et al., c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells. J Virol 2009; 83: 5014-5027.
42. Andersen MH, Svane IM, Becker JC, et al., The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007; 13: 5991-5994. (Pubitemid 350075053)
43. Paydas S, Ergin M, Erdogan S, et al., Thrombospondin-1 (TSP-1) and survivin (S) expression in non-Hogkin's lymphomas. Leuk Res 2008; 32: 243-250. (Pubitemid 351215546)
44. Raj D, Liu T, Samadashwily G, et al., Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 2008; 29: 194-201. (Pubitemid 351201759)
45. Zhou J, Bi C, Janakakumara JV, et al., Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 2009; 113: 4052-4062.
46. Zhao WL, Liu YY, Zhang QL, et al., PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. Blood 2008; 111: 3867-3871.
47. Johnson K, Shapiro-Shelef M, Tunyaplin C, et al., Regulatory events in early and late B-cell differentiation. Mol Immunol 2005; 42: 749-761.
48. Lin Y, Wong K, Calame K,. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 1997; 276: 596-599. (Pubitemid 27193684)
49. Ryan BM, O'Donovan N, Duffy MJ,. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009; 35: 553-562.